News | November 20, 2023
AskBio announces first patient randomized in Phase 1 Trial of AB-1005
Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels
Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
The company has raised US$4.5 million in funding for its AI operating system
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Total transaction value of the divestment is Rs. 3,660 million
Lack of technology transfer stands out as a formidable barrier
The newly developed adhesive is available in two different grades. Loctite WT 3001 and Loctite WT 3003 h
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
India is following a holistic and inclusive approach in alignment with the vison of Universal Health Coverage and the resolute commitment to ‘leave no one behind
Subscribe To Our Newsletter & Stay Updated
